APOE and Alzheimer disease: Interestingly, the ω-3 fatty acid docosahexaenoic acid (DHA), in combination with RXR agonist bexarotene, enhances LXR:RXR target gene expression of Abca1 and ApoE, reduces soluble forms of Aβ, and abrogates release of pro-inflammatory cytokines and mediators both in vitro and in a mouse model of AD [34].